Auris Medical Holding AG (NASDAQ:EARS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “

EARS has been the topic of a number of other reports. JMP Securities downgraded shares of Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 18th. Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Needham & Company LLC upped their price target on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, August 19th. Finally, Leerink Swann reissued a “buy” rating and set a $12.00 target price on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $8.88.

Shares of Auris Medical Holding AG (NASDAQ:EARS) opened at 1.65 on Monday. The company’s market capitalization is $56.64 million. The company has a 50-day moving average price of $2.69 and a 200 day moving average price of $3.54. Auris Medical Holding AG has a one year low of $1.55 and a one year high of $7.96.

A number of institutional investors have recently bought and sold shares of EARS. TFS Capital LLC increased its position in Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock valued at $160,000 after buying an additional 5,762 shares during the last quarter. Advisor Group Inc. acquired a new position in Auris Medical Holding AG during the second quarter valued at approximately $277,000. Finally, Bellevue Group AG acquired a new position in Auris Medical Holding AG during the first quarter valued at approximately $7,897,000. 30.95% of the stock is currently owned by hedge funds and other institutional investors.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

Get a free copy of the Zacks research report on Auris Medical Holding AG (EARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.